Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 5, 2007, Pages 689-695

  Campone, M ^a   Isambert, N ^b   Bourbouloux, E ^a   Maury, S ^a   Monin Baroille, P ^b   Berille, J ^c   Fumoleau, P ^b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Centre G E Leclerc   (France)

^c SANOFI   (France)

Author keywords

Cytotoxics; Phase I; SR271425; Thioxanthone

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; OXALIPLATIN; SR 271425; UNCLASSIFIED DRUG;

ACIDOSIS; ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BONE MARROW; BRAIN TUMOR; BREAST TUMOR; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG INFUSION; ELECTROCARDIOGRAM; FEMALE; FEMALE GENITAL TRACT TUMOR; HALF LIFE TIME; HEADACHE; HEALTH CENTER; HEMOPTYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; LIVER FUNCTION; MALE; MASS SPECTROMETRY; NAUSEA; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; QT PROLONGATION; RASH; SIDE EFFECT; SKIN DISCOLORATION; SOLID TUMOR; TUMOR BLEEDING; URINARY TRACT CANCER; VISUAL DISORDER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASMS; THIOXANTHENES;

EID: 33847125329     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0349-8     Document Type: Article

References (8)

1. Legha SS, Grose WE, Bodey GP (1978) Phase I study of Hycanthone. Cancer Treat Rep 62(8):1173-1176
2. Kovach JS, Moertel CG, Schutt AJ, Eagan RT (1979) Phase I study of Hycanthone. Cancer Treat Rep 63(11-12):1965-1969
3. Schutt AJ, Dalton RJ, Kovach JS et al (1983) Phase II study of Hycanthone in patients with advanced colorectal carcinoma. Cancer Treat Rep 67(6):593-594
4. LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK et al (2000) Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res 6:3088-3094
5. Stevenson JP, DeMaria D, Reilly D et al (1999) Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule. Cancer Chemother Pharmacol 44:228-234
6. Corbett TH, Panchapor C, Polin L et al (1999) Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs 17:17-27
7. Lorusso P, Wadler S, Loh E, Pilat MJ et al (2005) A phase I trial of SR271425 given as a one hour infusion every 3 weeks to patients with advances solid tumors. JCO 23(16S):2030
8. NCI-CTC V.3.0 (Refer to NCI CTCAE v.3.0 in the Study Reference Manual, or online at the following NCI website: http://www.ctep.cancer.gov/reporting/ctc. html)